This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Stock Mailbag: Sangamo Biosciences

Stocks in this article: SGMO NYMX ANX ONTY VVUS OREX AMAG

I'm told that some of Amag's largest shareholders aren't happy at all with this Allos merger. Whether that anger and frustration is enough to compel anyone to try to stop the deal from closing remains to be seen. What I do know, talking to some of Amag's shareholders, is that management needs to do a better job selling the merits of merging with Allos.

Lastly, you have to feel bad for Allos shareholders, who are really getting the shaft. The merger, as proposed, has no collar, only a fixed payout ratio, so the payday falls as Amag's stock price falls. The deal, as announced Wednesday morning, valued Allos at $2.44 a share, a smallish 18% premium. As of Thursday midday trading, the merger with Amag valued Allos at $2.05 -- technically a take-under, no premium.

If Allos shareholders want someone to blame for their shabby treatment, direct your ire to Warburg Pincus, Allos' largest shareholder, which wanted a speedy, no muss exit from its position, according to sources.


Brent B. asks, "Any new information or opinions on Nymox (NYMX)? Your last article on Nymox was open ended due to the lack of information given by CEO Paul Averback. This target industry is real and growing. If the product does close to expectations it should be a great stock. Just wondering if you have heard or learned anything new since your February article."

In May, Nymox issued a press release announcing the presentation of new "positive" data on its experimental drug NX-1207 for the treatment of enlarged prostate at a company-sponsored symposium held in conjunction with a medical meeting of urology experts.

I didn't attend the meeting, and since Nymox's press release was short on details, I asked the company to send me the NX-1207 slides or presentations used at its symposium. It sounded like a reasonable request but Nymox didn't respond.

Not an encouraging sign at all, just a continuation of Nymox's lack of transparency when it comes to NX-1207.

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs